Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGM-7354
- Development stage
- Phase 1
- Lead developer
- IGM Biosciences
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IGM-7354 is a pentameric immunoglobulin M (IgM) fusion protein that combines an anti-PD-L1 antibody with interleukin-15 (IL-15), designed for the treatment of solid and hematologic malignancies. The drug targets programmed death-ligand 1 (PD-L1) on tumor cells, selectively delivering IL-15 to the tumor microenvironment. This targeted delivery aims to stimulate immune cell proliferation—specifically natural killer (NK) cells and CD8+ T cells—enhancing anti-tumor immunity while potentially reducing systemic toxicity. IGM-7354 is being developed by IGM Biosciences and has entered Phase 1 clinical trials as a monotherapy in patients with relapsed or refractory solid tumors[1][2][3][5][6].
- Other names
- anti-PD-L1 antibody/IL-15 fusion protein
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on IGM-7354.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGM-7354.